Chemomab Therapeutics Ltd. (CMMB)


-0.13 (-12.38%)
Symbol CMMB
Price $0.92
Beta -0.241
Volume Avg. 0.06M
Market Cap 10.875M
Shares () -
52 Week Range 0.901-5.35
1y Target Est -
DCF Unlevered CMMB DCF ->
DCF Levered CMMB LDCF ->
ROE -101.88% Strong Sell
ROA -115.47% Strong Sell
Operating Margin -
Debt / Equity 0.64% Neutral
P/E -0.32 Neutral
P/B 0.46 Neutral


Consensus EPS

Upgrades & Downgrades

Latest CMMB news

Dr. Adi Mor George Ph.D.
NASDAQ Capital Market

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.